BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21718134)

  • 21. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
    Molin D; Linderoth J; Wahlin BE
    Br J Haematol; 2017 May; 177(3):449-456. PubMed ID: 28233899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
    Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
    Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
    Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
    Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
    Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
    Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.
    Grange F; Joly P; Barbe C; Bagot M; Dalle S; Ingen-Housz-Oro S; Maubec E; D'Incan M; Ram-Wolff C; Dalac S; Templier I; Esteve E; Quereux G; Machet L; Leduc M; Dereure O; Laroche L; Saiag P; Vergier B; Beylot-Barry M
    JAMA Dermatol; 2014 May; 150(5):535-41. PubMed ID: 24647650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.
    Pillon M; Mussolin L; Carraro E; Conter V; Aricò M; Vinti L; Garaventa A; Piglione M; Buffardi S; Sala A; Santoro N; Lo Nigro L; Mura R; Tondo A; Casale F; Farruggia P; Pierani P; Cesaro S; d'Amore ES; Basso G
    Br J Haematol; 2016 Nov; 175(3):467-475. PubMed ID: 27392319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia.
    Dujmovic D; Aurer I; Radman I; Serventi-Seiwerth R; Dotlic S; Stern-Padovan R; Dubravcic K; Santek F; Labar B
    Acta Haematol; 2012; 127(2):115-7. PubMed ID: 22212303
    [No Abstract]   [Full Text] [Related]  

  • 31. Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis.
    Liu ZL; Liu PP; Bi XW; Lei DX; Wang Y; Li ZM; Jiang WQ; Xia Y
    Cancer Med; 2019 Mar; 8(3):874-881. PubMed ID: 30706675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
    Oriol A; Ribera JM; Bergua J; Giménez Mesa E; Grande C; Esteve J; Brunet S; Moreno MJ; Escoda L; Hernandez-Rivas JM; Hoelzer D
    Cancer; 2008 Jul; 113(1):117-25. PubMed ID: 18457327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
    Choi MK; Jun HJ; Lee SY; Kim KH; Lim DH; Kim K; Ko YH; Kim WS; Kim SJ
    Ann Hematol; 2009 Nov; 88(11):1099-106. PubMed ID: 19288103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
    Tauro S; Cochrane L; Lauritzsen GF; Baker L; Delabie J; Roberts C; Mahendra P; Holte H
    Am J Hematol; 2010 Apr; 85(4):261-3. PubMed ID: 20201088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.
    Carella AM; de Souza CA; Luminari S; Marcheselli L; Chiappella A; di Rocco A; Cesaretti M; Rossi A; Rigacci L; Gaidano G; Merli F; Spina M; Stelitano C; Hohaus S; Barbui A; Puccini B; Miranda EC; Guida A; Federico M
    Leuk Lymphoma; 2013 Jan; 54(1):53-7. PubMed ID: 22712840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adult Burkitt's lymphoma: clinical and prognostic evaluation of 20 patients.
    Zinzani PL; Gherlinzoni F; Bendandi M; Salvucci M; Tura S
    Leuk Lymphoma; 1994 Aug; 14(5-6):465-70. PubMed ID: 7812206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
    Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult Burkitt lymphoma: advances in diagnosis and treatment.
    Aldoss IT; Weisenburger DD; Fu K; Chan WC; Vose JM; Bierman PJ; Bociek RG; Armitage JO
    Oncology (Williston Park); 2008 Nov; 22(13):1508-17. PubMed ID: 19133605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.